The aMAP score predicts long-term outcomes after resection of hepatocellular carcinoma: a multi-institutional analysis.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
04 Jan 2024
Historique:
received: 22 09 2023
revised: 22 11 2023
accepted: 03 01 2024
medline: 14 1 2024
pubmed: 14 1 2024
entrez: 13 1 2024
Statut: aheadofprint

Résumé

The aMAP score is a proposed model to predict the development of hepatocellular carcinoma (HCC) among high-risk patients with chronic hepatitis. The role of the aMAP score to predict long-term survival among patients following resection of HCC has not been determined. Patients undergoing resection for HCC between 2000 and 2020 were identified using a multi-institutional database. The impact of the aMAP score on long-term outcomes following HCC resection was assessed. Among 1377 patients undergoing resection for HCC, a total of 972 (70.6 %) patients had a low aMAP score (≤63), whereas 405 (29.4 %) individuals had a high aMAP score (≥64). aMAP score was associated with 5-year OS in the entire cohort (low vs high aMAP score:66.5 % vs. 54.3 %, p < 0.001). aMAP score predicted 5-year OS following resection among patients with HBV-HCC (low vs. high aMAP:68.8 % vs. 55.6 %, p = 0.01) and NASH/other-HCC (64.7 % vs. 53.7, p = 0.04). aMAP score could sub-stratify 5-year OS among patients undergoing HCC resection within (low vs. high aMAP:81.5 % vs. 67.4 %, p < 0.001) and beyond (55.9 % vs. 38.8 %, p < 0.001) Milan criteria. The aMAP score predicted postoperative outcomes following resection of HCC within and beyond Milan criteria. Apart from a surveillance tool, the aMAP score can also be used as a prognostic tool among patients undergoing resection of HCC.

Sections du résumé

BACKGROUND BACKGROUND
The aMAP score is a proposed model to predict the development of hepatocellular carcinoma (HCC) among high-risk patients with chronic hepatitis. The role of the aMAP score to predict long-term survival among patients following resection of HCC has not been determined.
METHODS METHODS
Patients undergoing resection for HCC between 2000 and 2020 were identified using a multi-institutional database. The impact of the aMAP score on long-term outcomes following HCC resection was assessed.
RESULTS RESULTS
Among 1377 patients undergoing resection for HCC, a total of 972 (70.6 %) patients had a low aMAP score (≤63), whereas 405 (29.4 %) individuals had a high aMAP score (≥64). aMAP score was associated with 5-year OS in the entire cohort (low vs high aMAP score:66.5 % vs. 54.3 %, p < 0.001). aMAP score predicted 5-year OS following resection among patients with HBV-HCC (low vs. high aMAP:68.8 % vs. 55.6 %, p = 0.01) and NASH/other-HCC (64.7 % vs. 53.7, p = 0.04). aMAP score could sub-stratify 5-year OS among patients undergoing HCC resection within (low vs. high aMAP:81.5 % vs. 67.4 %, p < 0.001) and beyond (55.9 % vs. 38.8 %, p < 0.001) Milan criteria.
DISCUSSION CONCLUSIONS
The aMAP score predicted postoperative outcomes following resection of HCC within and beyond Milan criteria. Apart from a surveillance tool, the aMAP score can also be used as a prognostic tool among patients undergoing resection of HCC.

Identifiants

pubmed: 38218690
pii: S1365-182X(24)00001-7
doi: 10.1016/j.hpb.2024.01.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Auteurs

Diamantis I Tsilimigras (DI)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Yutaka Endo (Y)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Francesca Ratti (F)

Department of Surgery, Ospedale San Raffaele, Milano, Italy.

Hugo P Marques (HP)

Department of Surgery, Curry Cabral Hospital, Lisbon, Portugal.

François Cauchy (F)

Department of Hepatobiliopancreatic Surgery, APHP, Beaujon Hospital, Clichy, France.

Vincent Lam (V)

Department of Surgery, Westmead Hospital, Sydney, Australia.

George A Poultsides (GA)

Department of Surgery, Stanford University, Stanford, CA, USA.

Irinel Popescu (I)

Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania.

Sorin Alexandrescu (S)

Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania.

Guillaume Martel (G)

Department of Surgery, University of Ottawa, Ottawa, Canada.

Minoru Kitago (M)

Department of Surgery, Keio University, Tokyo, Japan.

Alfredo Guglielmi (A)

Department of Surgery, University of Verona, Verona, Italy.

Tom Hugh (T)

Department of Surgery, The University of Sydney, School of Medicine, Sydney, Australia.

Luca Aldrighetti (L)

Department of Surgery, Ospedale San Raffaele, Milano, Italy.

Ana Gleisner (A)

Department of Surgery, University of Colorado, Denver, CO, USA.

Feng Shen (F)

Department of Hepatic Surgery IV, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.

Itaru Endo (I)

Yokohama City University School of Medicine, Yokohama, Japan.

Timothy M Pawlik (TM)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: tim.pawlik@osumc.edu.

Classifications MeSH